Castle Surgical promotes benefits of partial nephrectomy to treat kidney cancer at New York medical device event

{tortags,54793,1}{tortags,54793,1}NEW YORK, NY USA (Press Release) - October 24, 2012 -

New open and laparoscopic instruments simplify surgical procedures, improve patient outcomes, and reduce treatment costs by up to 85%

Castle Surgical, Inc. announced today that its Chief Executive Officer, Paras Patani, will deliver the keynote address at “Opportunities for Collaboration”, a networking event for Israeli-based medical device companies. The address, titled “The Future of Kidney Cancer Surgery: The Changing Standard of Care for Renal Cell Carcinoma,” will be presented at the Offices of Hodgson Russ LLP in Manhattan on Thursday, October 25th. Castle Surgical is a surgical devices company dedicated to promoting the use of partial nephrectomy and addressing the needs of the $800 million kidney cancer surgery market.

castlesurgCastle Surgical has developed a line of open and laparoscopic surgical instruments that greatly simplify the partial nephrectomy surgical procedure. The company’s patent-pending technologies offer the potential to improve patient clinical outcomes, reduce the risk of surgical complications, and lower treatment costs for kidney cancer surgery by 85% vs. the current standard of care.[1]

Partial nephrectomy, in which only the cancerous tumor is excised and most of the patient’s original kidney is left intact, is a vastly underutilized surgical option for treating kidney cancer. Although the procedure is advocated by the American Urologic Association (AUA) and the European Association of Urology (EAU) “whenever possible,” partial kidney removal is performed in only 20% of cancer operations today.[2, 3] In most cases, patients lose their entire kidney, called radical nephrectomy, even though most of the kidney tissue is still viable and healthy.

Furthermore, patients undergoing radical nephrectomy have a 38% higher risk of mortality from all causes and are 1.4 times more likely to experience a heart attack or stroke than those treated by partial nephrectomy instead.[4] Radical nephrectomy patients are also more likely to develop chronic kidney disease, potentially leading to renal insufficiency or renal failure, and require ongoing dialysis and expensive drug therapies.

Prior to founding Castle Surgical, Mr. Patani led a $60 million surgical devices unit at Covidien, a global top-10 medical devices company. He holds a BS in mechanical engineering from Rensselaer Polytechnic Institute and an MBA from Babson College.

“Opportunities for Collaboration: Israeli Medical Device Companies” will also feature presentations from 2P2D, a wireless telemedicine system for real-time monitoring and documentation of drug compliance and adherence during clinical trials; ApiFix, a minimally-invasive deformity correction system for adolescent idiopathic scoliosis patients; Leviticus Cardio, a non-invasive coplanar energy transfer system that supplies power to ventricular assist device (VAD) implants; and MediValve, a developer of innovative tools for precise placement in transcatheter aortic valve implantation (TAVI) procedures. The complimentary program will be held this Thursday from 3:45 – 9:00 PM at Hodgson Russ LLP, 1540 Broadway, 24th Floor, New York, NY. Those interested in attending may register at .

About Castle Surgical

Castle Surgical, Inc. is a surgical devices company committed to making partial nephrectomy the standard of care for the treatment of kidney cancer. The company provides urology surgeons open and laparoscopic surgical instruments to make renal cell carcinoma procedures significantly easier to perform. The company’s patent-pending technologies offer the potential to improve patient clinical outcomes, reduce the risk of surgical complications, and lower treatment costs for kidney cancer surgery by 85% vs. the current standard of care. For more information, visit castlesurgical.com.

References:

  1. Mariotto, et al., “Projections of the Cost of Cancer Care in the United States: 2010-2020”. Journal of the National Cancer Institute (2011).
  2. AUA, “AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors”. American Urologic Association (2009).
  3. Ljungberg, et al., “EAU Guidelines on Renal Cell Carcinoma: The 2010 Update”. European Urology (2010).
  4. Huang, et al., “Partial Nephrectomy Versus Radical Nephrectomy in Patients with Small Renal Tumors–is There a Difference in Mortality and Cardiovascular Outcomes?” The Journal of Urology (2009).

 

Contacts:
Paras Patani, Chief Executive Officer
Castle Surgical, Inc.
Office: (212) 933-4493
Email:

Cheryl Lechok, President
Cheryl Lechok Communications, LLC
Office: (203) 961-9280
Email:

###

Castle Surgical, Inc.

 

[ PRESS RELEASE ]

 

 

email news signup